Land: Ísrael
Tungumál: enska
Heimild: Ministry of Health
COAGULATION FACTOR II (HUMAN); COAGULATION FACTOR IX (HUMAN- RFIXFC); COAGULATION FACTOR VII (HUMAN); COAGULATION FACTOR X (HUMAN); PROTEIN C; PROTEIN S ANTIGEN
CSL BEHRING LTD., ISRAEL
B02BD01
POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
COAGULATION FACTOR II (HUMAN) 400 - 960 IU; COAGULATION FACTOR VII (HUMAN) 200 - 500 IU; COAGULATION FACTOR IX (HUMAN- RFIXFC) 400 - 620 IU; COAGULATION FACTOR X (HUMAN) 440 - 1200 IU; PROTEIN C 300 - 900 IU; PROTEIN S ANTIGEN 240 - 760 IU
I.V
Required
CSL BEHRING GmbH, GERMANY
COAGULATION FACTOR IX, II, VII AND X IN COMBINATION
Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required.
2017-03-31
העדוה העדוה לע לע הרמחה הרמחה ( ( עדימ עדימ ןולעב )תוחיטב ןולעב )תוחיטב ל ל אפור אפור ןכדועמ( ןכדועמ( 05.2013 05.2013 ) ) ךיראת 31/08/2014 םש רישכת תילגנאב רפסמו :םושירה BERIPLEX ® P/N 500 ( 147 88 33309 00 ), BERIPLEX ® P/N 250 ( 147 87 33308 00 ) _ םש לעב םושירה GENMEDIX דבלב תורמחהה טורפל דעוימ הז ספוט ! תושקובמה תורמחהה ןולעב קרפ יחכונ טסקט שדח טסקט 4.2 POSOLOGY AND METHOD OF ADMINISTRATION BLEEDING AND PERIOPERATIVE PROPHYLAXIS OF BLEEDINGS DURING VITAMIN K ANTAGONIST TREATMENT. The dose will depend on the INR before treatment and the targeted INR. In the following table approximate doses (ml/kg body weight of the reconstituted product and IU FIX/kg b.w.) required for normalisation of INR (e.g. ≤ 1.3) at different initial INR levels are given. Initial INR 2.0 – 3.9 4.0 – 6.0 > 6.0 Approximate dose ml/kg body weight 1 1.4 2 BLEEDING AND PERIOPERATIVE PROPHYLAXIS OF BLEEDINGS DURING VITAMIN K ANTAGONIST TREATMENT. The dose will depend on the INR before treatment and the targeted INR. The pre-treatment INR should be measured as close as possible to the time of dosing in order to calculate the appropriate dose of Beriplex. In the following table approximate doses (ml/kg body weight of the reconstituted product and IU Factor IX/kg b.w.) required for normalisation of INR (e.g. ≤ 1.3) at different initial INR levels are given. Pre-treatment INR 2.0 – 3.9 4.0 – 6.0 > 6.0 Approximate dose ml/kg body weight 1 1.4 2 Approximate dose IU (Factor IX)/kg body weight 25 35 50 It is recommended that the maximum single dose should not exceed 5000 IU FIX. The correction of the vitamin K antagonist-induced impairment of haemostasis is reached at the latest 30 minutes after the injection and will persist for approximately 6 – 8 hours. However, the effect of vitamin K, if administered simultaneously, is usually achieved within 4 – 6 Lestu allt skjalið
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT BERIPLEX ® P/N 250 , powder and solvent for solution for injection. BERIPLEX ® P/N 500, powder and solvent for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Beriplex is presented as powder and solvent for solution for injection containing human prothrombin complex. The product nominally contains the following IU of the human coagulation factors tabled below: NAME OF THE INGREDIENTS CONTENT AFTER RECONSTITUTION (IU/ML) BERIPLEX P/N 250 CONTENT PER VIAL (IU) BERIPLEX P/N 500 CONTENT PER VIAL (IU) ACTIVE INGREDIENTS Human coagulation factor II 20 – 48 200 – 480 400 – 960 Human coagulation factor VII 10 – 25 100 – 250 200 – 500 Human coagulation factor IX 20 – 31 200 – 310 400 – 620 Human coagulation factor X 22 – 60 220 – 600 440 – 1200 FURTHER ACTIVE INGREDIENTS Protein C 15 – 45 150 – 450 300 – 900 Protein S Antigen 12 – 38 120 – 380 240 – 760 The total protein content is 6 – 14 mg/ml of reconstituted solution. The specific activity of factor IX is 2.5 IU per mg total protein. The activities of all coagulation factors as well as Protein C and S (antigen) have been tested according to the current valid international WHO-Standards. Excipients with known effect: Sodium up to 343 mg (approximately 15 mmol) per 100 ml solution. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection. White or slightly coloured powder or friable solid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _POSOLOGY _ _ _ Only general dosage guidelines are given below. Treatment should be initiated under the supervision Lestu allt skjalið